248 related articles for article (PubMed ID: 22003496)
1. Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules.
Hanif M; Nazarov AA; Legin A; Groessl M; Arion VB; Jakupec MA; Tsybin YO; Dyson PJ; Keppler BK; Hartinger CG
Chem Commun (Camb); 2012 Feb; 48(10):1475-7. PubMed ID: 22003496
[TBL] [Abstract][Full Text] [Related]
2. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
3. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
4. Organometallic ruthenium anticancer complexes inhibit human glutathione-S-transferase π.
Lin Y; Huang Y; Zheng W; Wang F; Habtemariam A; Luo Q; Li X; Wu K; Sadler PJ; Xiong S
J Inorg Biochem; 2013 Nov; 128():77-84. PubMed ID: 23942162
[TBL] [Abstract][Full Text] [Related]
5. Design of Ru-arene Complexes for Antitumor Drugs.
Su W; Li Y; Li P
Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
[TBL] [Abstract][Full Text] [Related]
6. Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery.
Pichler V; Mayr J; Heffeter P; Dömötör O; Enyedy ÉA; Hermann G; Groza D; Köllensperger G; Galanksi M; Berger W; Keppler BK; Kowol CR
Chem Commun (Camb); 2013 Mar; 49(22):2249-2251. PubMed ID: 23396381
[TBL] [Abstract][Full Text] [Related]
7. Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.
Hu W; Luo Q; Ma X; Wu K; Liu J; Chen Y; Xiong S; Wang J; Sadler PJ; Wang F
Chemistry; 2009 Jul; 15(27):6586-94. PubMed ID: 19533706
[TBL] [Abstract][Full Text] [Related]
8. Complexation with organometallic ruthenium pharmacophores enhances the ability of 4-anilinoquinazolines inducing apoptosis.
Zheng W; Luo Q; Lin Y; Zhao Y; Wang X; Du Z; Hao X; Yu Y; Lü S; Ji L; Li X; Yang L; Wang F
Chem Commun (Camb); 2013 Nov; 49(87):10224-6. PubMed ID: 23856988
[TBL] [Abstract][Full Text] [Related]
9. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes.
Yan YK; Melchart M; Habtemariam A; Sadler PJ
Chem Commun (Camb); 2005 Oct; (38):4764-76. PubMed ID: 16193110
[TBL] [Abstract][Full Text] [Related]
10. Highly cytotoxic trithiophenolatodiruthenium complexes of the type [(η6-p-MeC6H4Pri)2Ru2(SC6H4-p-X)3]+: synthesis, molecular structure, electrochemistry, cytotoxicity, and glutathione oxidation potential.
Giannini F; Furrer J; Ibao AF; Süss-Fink G; Therrien B; Zava O; Baquie M; Dyson PJ; Stěpnička P
J Biol Inorg Chem; 2012 Aug; 17(6):951-60. PubMed ID: 22707191
[TBL] [Abstract][Full Text] [Related]
11. Effect of cysteine thiols on the catalytic and anticancer activity of Ru(II) sulfonyl-ethylenediamine complexes.
Chen F; Romero-Canelón I; Habtemariam A; Song JI; Banerjee S; Clarkson GJ; Song L; Prokes I; Sadler PJ
Dalton Trans; 2022 Mar; 51(11):4447-4457. PubMed ID: 35226015
[TBL] [Abstract][Full Text] [Related]
12. Chlorambucil conjugates of dinuclear p-cymene ruthenium trithiolato complexes: synthesis, characterization and cytotoxicity study in vitro and in vivo.
Stíbal D; Therrien B; Süss-Fink G; Nowak-Sliwinska P; Dyson PJ; Čermáková E; Řezáčová M; Tomšík P
J Biol Inorg Chem; 2016 Jul; 21(4):443-52. PubMed ID: 27040952
[TBL] [Abstract][Full Text] [Related]
13. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
14. Dinuclear Organoruthenium Complexes Exhibiting Antiproliferative Activity through DNA Damage and a Reactive-Oxygen-Species-Mediated Endoplasmic Reticulum Stress Pathway.
Zhao J; Li S; Wang X; Xu G; Gou S
Inorg Chem; 2019 Feb; 58(3):2208-2217. PubMed ID: 30675781
[TBL] [Abstract][Full Text] [Related]
15. Subcellular localization and transport kinetics of ruthenium organometallic anticancer compounds in living cells: a dose-dependent role for amino acid and iron transporters.
Klajner M; Licona C; Fetzer L; Hebraud P; Mellitzer G; Pfeffer M; Harlepp S; Gaiddon C
Inorg Chem; 2014 May; 53(10):5150-8. PubMed ID: 24786362
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of cytotoxicity by combining pyrenyl-dendrimers and arene ruthenium metallacages.
Pitto-Barry A; Zava O; Dyson PJ; Deschenaux R; Therrien B
Inorg Chem; 2012 Jul; 51(13):7119-24. PubMed ID: 22716166
[TBL] [Abstract][Full Text] [Related]
17. Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development.
Babak MV; Meier SM; Legin AA; Adib Razavi MS; Roller A; Jakupec MA; Keppler BK; Hartinger CG
Chemistry; 2013 Mar; 19(13):4308-18. PubMed ID: 23341078
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of iridium and ruthenium complexes with (N,N), (N,O) and (O,O) coordinating bidentate ligands as potential anti-cancer agents.
Lucas SJ; Lord RM; Wilson RL; Phillips RM; Sridharan V; McGowan PC
Dalton Trans; 2012 Dec; 41(45):13800-2. PubMed ID: 23015068
[TBL] [Abstract][Full Text] [Related]
19. Selective, cytotoxic organoruthenium(II) full-sandwich complexes: a structural, computational and in vitro biological study.
Loughrey BT; Cunning BV; Healy PC; Brown CL; Parsons PG; Williams ML
Chem Asian J; 2012 Jan; 7(1):112-21. PubMed ID: 22095971
[TBL] [Abstract][Full Text] [Related]
20. Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: synthesis, characterisation and preliminary evaluation of biological activity.
Ji L; Zheng W; Lin Y; Wang X; Lü S; Hao X; Luo Q; Li X; Yang L; Wang F
Eur J Med Chem; 2014 Apr; 77():110-20. PubMed ID: 24631730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]